| Literature DB >> 31775255 |
Zhiwei Liu1,2, Tianheng Gao3, Ying Yang4, Fanxin Meng1, Fengping Zhan1, Qichen Jiang4, Xian Sun1,5.
Abstract
Seaweeds are some of the largest producers of biomass in the marine environment and are rich in bioactive compounds that are often used for human and animal health. Porphyran and carrageenan are natural compounds derived from red seaweeds. The former is a characteristic polysaccharide of Porphyra, while the latter is well known from Chondrus, Gigartina, and various Eucheuma species, all in Rhodophyceae. The two polysaccharides have been found to have anti-cancer activity by improving immunity and targeting key apoptotic molecules and therefore deemed as potential chemotherapeutic or chemopreventive agents. This review attempts to review the current study of anti-cancer activity and the possible mechanisms of porphyran and carrageenan derived from red seaweeds to various cancers, and their cooperative actions with other anti-cancer chemotherapeutic agents is also discussed.Entities:
Keywords: anti-cancer; carrageenan; porphyran; seaweed
Mesh:
Substances:
Year: 2019 PMID: 31775255 PMCID: PMC6930528 DOI: 10.3390/molecules24234286
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Typical repetitive structures in porphyran [38]: (a) G-A; (b) G-A2M; (c) G-L6S; (d) G6M-A. G: 1,3-linked β-d-galactose; A: 1,4-linked 3,6-anhydro-α-l-galactose; A2M: 1,4-linked 2-O-methyl-3,6-anhydro-α-l-galactose; L6S: 1,4-linked α-l-galactose 6-sulfate; G6M: 1,3-linked 6-O-methyl-β-d-galactose.
Anti-cancer activity and possible mechanisms of porphyran.
| Source | Target | Type of Activity | Possible Mechanisms | References |
|---|---|---|---|---|
|
| Mice implanted with Ehrlich carcinoma and Meth A fibrosarcoma | Appreciable inhibition of tumor growth | Not referred | [ |
| AGS and HT-29 cancer cells | Antiproliferation | [ | ||
| SGC-7901 and 95D cancer cell lines | [ | |||
| Hep3B cells | Antiproliferation and cell cycle blocked in the G2/M phase | Upregulation of p21 and p53, while negatively regulating cyclin B1and CDK1 | [ | |
| HO-8910, MCF-7, K562, and SMMC-7721 cells | Antiproliferation and cell cycle arrested at the G0/G1or the G2/M check points | Not referred | [ | |
| HT-29 colon cancer cells and AGS gastric cancer cells | Antiproliferation and apoptosis induced | Increasing caspase-3 activity | [ | |
| Commodity provided by Korea Bio Polymer (KBP) company | AGS human gastric cancer cells. | Negatively regulating IGF-IR phosphorylation and inducing caspase-3 activation | [ |
Figure 2Possible mechanism in the anti-cancer activity of porphyran and carrageenan.
Figure 3Chemical structure of carrageenans [64]: (a) δ-carrageenan; (b) α-carrageenan; (c) γ-carrageenan; (d) β-carrageenan; (e) μ-carrageenan; (f) κ-carrageenan; (g) ν-carrageenan; (h) ι-carrageenan; (i) λ-carrageenan; and (j) θ-carrageenan.
Anti-cancer activity and possible mechanisms of carrageenans.
| Source | Target | Type of Activity | Possible Mechanisms | References |
|---|---|---|---|---|
| λ-carrageenan purchased from Sigma-Aldrich | B16-F10 and 4T1 bearing mice | Inhibition of tumor growth and improving immune system | Increasing the number of tumor-infiltrating M1 macrophages, DCs, and more activated CD4+ CD8+ T lymphocytes and enhancing the secretion of IL17A in spleen and significantly increase the level of TNF-α in tumor | [ |
| Carrageenan oligosaccharides derived from | S180-bearing mice | Increase macrophage phagocytosis, the form of antibody secreted by spleen cells, spleen lymphocyte proliferation, NK cells activity, serumal IL-2 and TNF-a level | [ | |
| κ-carrageenan and λ-carrageenan purchased from Sigma-Aldrich | HeLa cells | Cell cycle delayed in G2/M phase or in both G1 and G2/M phase | Not referred | [ |
| κ-selenocarrageenan consisted of selenium and κ-carrageenan | HepG2 cells | Cell cycle delayed in S phase | Upregulating Cyclin A and chk2 protein and down-regulating Cdc25A and cdk2 expression. | [ |
| ι-Carrageenan | Human osteosarcoma cell line | Apoptosis induced and Cell cycle delayed in G1 phase | Downregulation of the Wnt/β-catenin signaling pathway through suppressing LRP6 expression and phosphorylation | [ |
| κ-carrageenan oligosaccharides prepared from κ-carrageenan with enzyme | MCF-7 xenograft tumor | Antiproliferation and anti-angiogenic | Negative regulation of human VEGF, bFGF, bFGFR, and CD105 | [ |